Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of AZD4831 in Healthy Male Subjects
NCT02712372Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (10 arms), sponsored by AstraZeneca. Primary endpoints: Frequencies of adverse events, Supine blood pressure and 8 more. Started Jun 2016; status: terminated.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02712372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712372.